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Summary
Aim. The aim of the study is to examine the change of emotional distress and fatigue influenced by a psychosocial intervention 
programme in women with non metastatic breast cancer.
Material and methods. The research was carried out in Budapest at the Department of Radiodiagnostics of the National In-
stitute of Oncology. The sample: n=173, (intervention group = 86, control = 87) (34 women have participated in the study), 
control = 87. The Shortened Beck Depression Inventory, the Spielberger’s State-Trait Anxiety Inventory and the EORTC 
QLQ C30 quality of life questionnaire have been used for the research. 
Results. There was a significant improvement in patients in all three assessed outcome variables. Depression symptoms: 
F(1.72) = 4.347 p = 0.041; anxiety: F(1.65) = 6.021 p = 0.017; fatigue: F(1.78) = 15.060 p = 0.000.
Conclusions. The early recognition of the presence of anxiety and depression, and their medical and psychological support are 
crucial. The psychosocial intervention efficiently helped the reduction of emotional distress and fatigue.
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INTRODUCTION
According to the 2008 statistics of the World Health 
Organization, there were 34 million people diagnosed 
with cancer. There are about 12.5 million registered new 
cases, and 7.6 million people die of cancer every year 
around the world. Caring for patients with malignant tu-
mours is causing more and more difficulties for health 
services. According to John Seffrin, the chief executive 
officer of the American Cancer Society, cancerous dis-
eases have to be treated as global epidemic (1). By 2030 
the number of new cancer patients is estimated to rise 
to 26 million, and 11.5 million people will die of malig-
nant tumours. In Hungary, during the last 60 years, the 
number of cancer cases has also gradually risen, and in 
this respect we are at the top of the statistics among the 
EU state members (1, 2). Breast cancer is the most com-
mon malignant disease in women worldwide. As a re-
sult of early recognition and treatment, in the developed 
countries, including Hungary, the relative 5-year-survival 
rate is about 80% (1, 3). The diagnosis of breast cancer 
usually comes as a shock, accompanied by feelings of 
a threat to life and uncertainty. The state of anxiety and 
hopelessness has been proved to cause a decline in the 
health-related quality of life (4). The most common symp-
toms, such as depression, anxiety and vital exhaustion, 
can persist for years after the diagnosis (5, 6).
The number of cases affected by clinical anxiety and 
depression is much smaller, but reserches suggest that 
the presence of symptoms of subclinical anxiety and de-
pression adversely affects everyday life management and 
the experience of quality of life. Most authors suggest that 
the presence of psychological distress is 50%; these are 
mainly adjustment difficulties accompanied by anxiety 
and depression. Derogatis found psychological disor-
ders in 47% of the cases (7). In a large sample research 
(4496 patients), the prevalence of depression showed 
52% (8). Hopwood found close correlation between de-
pression and anxiety; 35% of the patients were character-
ised by this score, and he did not register any significant 
improvement at the 5-year follow up either (9). 
Concerning the subject, only a few studies have 
been conducted in Hungary.There has been a national 
representative study carried out by Hungarostudy 2002, 
surveying the physical and mental health of the adult 
population of Hungary, and the relationship between 
health indicators and the environmental, social and 
economic background. According to their research re-
sults, the incidence of clinically significant depression 
rate in women affected with cancer was 28.5%, while 
in men it was 27.4% (10). According to the results of a 
recent study (11), one tenth of women with breast can-
cer showed depression reaching the clinical border, and 
nearly two thirds of them had mild depression symp-
toms. The symptoms of anxiety were shown in one third 
of the patients, and 20% of these had severe state-trait 
anxiety. These results confirm the clinical experiences 
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published by Riskó (12), and are also related to the 
sources of similar studies (13).
Beside distress, one of the most common side-effects 
of conventional oncology treatments is vital exhaustion, 
with its defining characteristics: feelings of excessive fa-
tigue and lack of energy and increasing irritability. Nor-
mally, there is a strong correlation between these symp-
toms and depression (14, 6).
Nowadays it is more and more important that the 
patients are provided with psychological and emotional 
support, and there is more emphasis put on promoting 
the ability for spiritual and emotional adjustment, en-
couraging coping, and improving psychosocial quality 
of life. During this process, psychosocial interventions 
have outstanding significance; in complex therapies for 
cancerous afflictions, the role of onco-psychology and 
integrated psychosocial care has become increasingly 
important (15).
The majority of the studies assesing patients with 
breast-cancer confirms the beneficial effects of psycho-
social interventions in reducing emotional distress and 
also in impoving quality of life (16-20). 
MATERIAL AND METHODS
In 2009-2010, a comprehensive psycho-oncology re-
search was conducted, intending to develop a complex, 
complementary rehabilitation programme in addition 
to the conventional medical cancer treatment, in order 
to improve health and quality of life, strengthen coping 
abilities, and increase the life expectancy of patients suf-
fering from cancer. As first steps of this research, cross-
sectional studies were carried out, then a randomized 
sample was introduced to a complex, psychosocial in-
tervention programme. 
Our present study explores the variation of three 
commonly characteristicsymptoms of breast cancer fol-
lowing a psychosocial intervention programme: 
1. Variation of depression and anxiety affected by the 
programme.
2. Variation of vital exhaustion, fatigue affected by the 
programme.
The assessed sample and methodologies
173 women agreed to participate in our research, all 
suffering from malignant breast cancer (C50) and who 
were currently undergoing medical treatment because 
of their illness. The research was carried out in Buda-
pest at the Department of Radiodiagnostics of the Na-
tional Institute of Oncology, with the permission of the 
Institute’s Ethical Committee. During the assessments 
an eight-page self-assessment form was used that took 
50 minutes to be completed. The sample (n = 173) was 
randomly divided into treatment (n = 86) and control 
group (n = 87).Patients assigned to the experimental 
group were sent a letter of information, followed by tele-
phone contact. 36 patients agreed to participate in the 
programme. All participants attended the first interview. 
The 36 patients were divided into two groups; between 
September and December 2009 (group 1) and between 
February and June 2010 (group 2). Two patients left the 
intervention; hence the final number of the participants 
was 34. Two measurements were carried out: one before 
the programme (1st measurement – T1) and one after the 
programme (2nd measurement – T2). The first question-
naires were completed during mammographic investiga-
tion, and then the participants received the other packag-
es by post. 51 participants of the control-group (out of 87) 
returned the questionnaire. Social-demographic charac-
teristics of the sample are shown in table 1.
Concerning the demographic characteristics of the 
treatment and the control group, there were differences in 
education (the treatment group had more patients with at 
least secondary school); concerning the family medical 
history, there was a difference in the occurrence of can-
cerous affections (the control group had higher number 
of family members affected by tumours) (tab. 1).
The psychosocial intervention programme consisted 
of three main parts: a five-day residential life-style camp, 
where the patients received theoretical and a practical 
training related to healthy living, the incorporation of the 
acquired knowledge into everyday life-management, and 
finally a 14-week group psychotherapy, 5 hours a week.
Measures 
Shortened Beck Depression Inventory BDI
The Shortened Beck Depression Inventory BDI was 
used to determine severity, and explore and follow up de-
pression (21). The shortened version has nine items, that 
are related to social withdrawal, indecisiveness, change 
of sleep pattern, fatigue, hypochondria, inability towork, 
pessimism, lack of contentment and joy, and feelings of 
self-reproach. They can be scored by the patient between 
1 and 4 (from ‘not at all characteristic’ to ‘totally character-
istic’). High correlation (r = 0.92) between the total scores 
of the Shortened and the Full version confirms the reliabil-
ity and applicability of the Shortened version. Concerning 
the severity of the depression, the Shortened Beck Inven-
tory has the following categories: 0-9: not depressed, 
10-18: mild depression, 19-25: moderate depression, 
above 26 points: severe depression. According to clinical 
validity, the borderline for clinical depression is 19 points. 
The reliability of the questionnaire on the sample proved 
adequate (Cronbach-alpha = 0.86) (22).
Spielberger’s State-Trait Anxiety Inventory (STAI-T)
The Spielberger’s State-Trait Anxiety Inventory STAI-T 
measures the levels of trait-anxiety and shows the level 
of predisposition to anxiety. The questionnaire consists 
of 20 questions. Answers can be recorded on a four-
point Likert Scale. The choice of answers is as follows: 
1 – not at all, 2 – somewhat, 3 – quite, 4 – very much). 
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Table 1. Demographic characteristics of study sample by groups at T1.
Treatment group (N = 36) Control group (N = 87) p
Age (mean and SD) 53.17 (7.66) 52.09 (9.15) t = 0.61 ns.
Duration of the disease (mean and SD) 2.47 (0.47) 2.55 (0.86) t = 0.45 ns.
Time spent since surgery (mean and SD) 2.30 (0.74) 2.30 (0.79) t = 0.04 ns.
Education: N (%)
primary or vocational school
secondary school or higher
1 (2.8%)
35 (97.2%)
19 (22.1%)
67 (77%) p = 0.007*
Marital status: N (%)
lack of stable relationship
stable relationship
14 (38.9%)
22 (61.1%)
21 (24.1%)
66 (75.9%)
χ2 = 2.72
ns.
Having Children: N (%)
no
yes 
6 (16.7%)
30 (83.3%)
6 (6.9%)
81 (93.1%)
χ2 = 2.76
ns.
Economic activity: N (%)
active
inactive
17 (47.2%)
19 (52.8%)
42 (48.3%)
45 (51.7%)
χ2 = 0.01
ns.
History of family cancer N (%)
no cancer 
had cancer
8 (22.2%)
28 (77.8%)
42 (68.3%)
45 (51.7%)
χ2 = 7.16
p < 0.01
SD – Standard Deviation; ns.= non-significant; *Fisher’s exact test
Minimum 20, maximum 80 points are achievable. Stan-
dard scores in female population: mean: 45.37; std. de-
viation: 7.97. In the sample, the Cronbach-alpha coef-
ficient is 0.84 (23, 24).
Quality of Life Questionnaire  
(EORTC QLQ C30 BR23)
For measuring quality of life, the EORTC QLQ C30 
questionnaire was used that was developed by the 
Quality of Life Team of the European Organisation 
for Research and Treatment of Cancer (EORTC) (25). 
It consists of 30 items, andis divided into 3 scales. These 
are: 1) Global quality of life, 2) Functional quality of life 
and 3) Symptom-related quality of life. Global quality of 
life is assessed by two questions: “How would you rate 
the overall state of your health last week?” and “How 
would you rate the general quality of life last week?” The 
answers have to be indicated on a 1 to 7 scale, 1 = very 
bad, 7=excellent. Functional quality of life scales as-
sess: physical functioning, role functioning, emotional 
functioning, cognitive functioning and social function-
ing. Symptom-related quality of life scales measure: fa-
tigue, nausea, pain, dyspnoea, change in sleep pattern, 
loss of appetite, constipation, diarrhoea, and financial 
difficulties. Answers are recorded in a four-point Likert-
scale: 1 – not at all characteristic, 2 – somewhatcharac-
teristic, 3 – characteristic, 4 – very much characteristic. 
The Cronbach-alpha coefficient for this questionnaire is 
between 0.62 and 0.89. The European Organisation for 
the Research and Treatment of Cancer (EORTC) has 
made the Hungarian translation of the test available. 
These tests have previously been used only a few times 
in Hungary; therefore, their validation on a national sam-
ple is also one of the objectives of our study. Out of the 
symptom scales, the present study assesses the results 
of the fatigue scale. The Cronbach-alpha coefficients of 
the tests appliedon our sample are shown in table 2.
Table 2. Reliability of scales at T1 and at T2.
Scale
Number 
of items
Cronbach-α
at T1
Cronbach-α
at T2
Anxiety (STAI) 20 0.889 0.904
Depression  
(BDI-Short)
9 0.847 0.884
EORTC-fatigue 3 0.810 0.789
HYPOTHESES 
1. We hypothesise that, following the intervention, the 
mood-related outcome measurements (anxiety, de-
pression) in the assessed experimental group will 
show improvement, while the control group will show 
no change (to be verified by using the Repeated 
Measures Analysis of Variance assessing Time X 
Group Interaction).
2. We hypothesise that, in the intervention group, the 
EORTC fatigue measurement (one of the quality of life 
measurements) will improve following the interven-
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tion, while the control group will show no change (to 
be verified by using the Repeated Measures Analysis 
of Variance assessing Time X Group Interaction).
Applied Statistical Methods
As the first step, we compared the experimental 
group with the control group at the initial data collection 
(T1). Secondly, at the second data collection (T2), we 
assessed the control group to measure any differences 
between those who returned the questionnaires and 
those who did not. As the third step, we compared the 
changes occurred since the first data collection in both 
the experimental and the control group. For the analysis 
of categorical variables, we used the Chi-square test or 
Fisher-exact test,and Analysis of Variance was used for 
comparing variables for statistical significance.
RESULTS
1. Comparison of the experimental and the control 
group at the initial data collection: According to the 
results of the variance analysis when looking at the 
questionnaires completed at T1, the only difference 
between the two groups appeared in the EORTC fa-
tigue symptom scale. F(1.119) = 4.298 (Mexperimental: 
39.20, SD: 18.30; Mcontrol: 30.46, SD: 22.30). Mem-
bers of the experimental group started off with higher 
scores in the fatigue scales.
2. Comparison of the scores within the control group, be-
tween patients who returned the questionnaires and 
who did not: We assessed whether there were any 
significant differences concerning the psychological 
scales of the questionnaires within the control group 
between the patients who returned the tests (N = 51) 
and the patients who did not (N = 36). According to 
the analysis, there were no differences between the 
scores of the two groups, and neither was a differ-
ence concerning the demographic characteristics. 
3. Changes occurring in the experimental and the con-
trol group between T1 and T2 (levels of anxiety and 
depression, fatigue). We applied repeated measures 
analysis of variance, where in the within-subjects 
design we assessed along the data collection date 
(time) the group affiliation (experimental vs. control) X 
time interaction (tab. 3). As an extra factor the educa-
tion aspect was brought into the analysis, as the two 
groups showed major differences at T1.
The repeated measures analysis of variance 
showed significant changes in all three assessed di-
mensions: 
Anxiety F(1.65) = 6.021, p = 0.017 (fig. 1)
Depression F(1.72) = 4.347, p = 0.041 (fig. 2)
EORTC Fatigue F(1.78) = 15.060, p = 0.000 (fig. 3)
Table 3. Mean scores (Standard Deviations) of scales at T1, T2 by group (intervention vs. control).
Before treatment (T1) After treatment (T2)
Intervention group Control group Intervention group Control group
Anxiety 44.50 (9.04) 43.23 (10.53) 39.37 (9.13) 42.58 (11.34)
Depression 12.34 (3.56) 12.37 (3.88) 11.44 (2.27) 12.63 (4.96)
EORTC-fatigue 39.39 (18.65) 31.25 (22.42) 23.90 (15.57) 31.37 (24.48)
Fig. 1. Anxiety before treatment and after treatment.
Fig. 2. Depression before treatment and after treatment.
Fig. 3. Fatigue before treatment and after treatment.
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These results show that the affiliation of the members 
had an important influence on the positive changes of 
the listed measurements (tab. 3), namely patients who 
achieved favourable scores at T2 in comparison with 
T1 were those who participated the intervention pro-
gramme. We assessed the education factor too, but it 
had no influence on the analysed variables of the pres-
ent study. 
DISCUSSION 
Our research aimed to assess the effectiveness of 
a complex, comprehensive, psychosocial intervention-
al programme, affecting different levels of attitudes to 
health, life management and spiritual function in women 
with breast cancer. In order to enhance synergic effects, 
we tried to integrate numerous methods into the pro-
gramme that according to the data of related literature 
can facilitate the spiritual growth and the physical heal-
ing of the patients. Our general aim was to strengthen 
the coping ability, to improve the quality of life, to fa-
cilitate cognitive emotional process, and to reduce the 
chances of remission. Our present study is focused on 
the changes of the disease characteristic symptoms: 
emotional distress, and vital exhaustion, fatigue in the 
light of the influence of the programme. 
Depression and anxiety has been proved to cause a 
decline in health and deterioration of quality of life. A de-
pressed, hopeless state, that full of anxiety is known to 
influence the patients’ quality of life. The psychologi-
cal distress influences the physical comfort, the sense 
of well-being and the physical symptom perception 
(4, 13). The intervention proved to be effective, as all 
three symptoms of the patients have been significantly 
reduced. The programme successfully helped reducing 
anxiety and depression; the intervention group showed 
a significant improvement in their moods in comparison 
of the control group. An important measurement of the 
quality of life, the vital exhaustion, the general fatigue 
syndrome has also significantly improved. Just as the 
results of other researchers, these findings prove the ef-
fectiveness of psychosocial interventions, and psycho-
therapeutic procedures (16-18, 20).
According to the results we find it very important and 
suggest a regular and routine screening of psychologi-
cal distress in patients with cancer. Beside the risk of 
clinical distress, the subclinical group also has to be 
monitored. The early recognition of anxiety and depres-
sion, and an appropriate support and treatment are cru-
cial. They fundamentally influence the patients’ quality 
of life; they can encourage the patients’ co-operation, 
and evoke their fighting spirit. 
Our study and the related similar researches also 
bear an important health care policy message: psycho-
social interventions are largely cost-effective – for a small 
investment we can achieve a marked improvement in 
health and quality of life. Nowadays in the field of on-
cology the specialised onco-psychological services are 
underrepresented; most of the patients cannot access 
these kind of support (26, 27). High standard oncology 
services fulfilling the high expectations of our modern 
era cannot lack the knowledge of related sciences, the 
integrated psychosocial interventions (15). 
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